New Hampshire Medical Cannabis Program — Patient Guide and Updates

Executive Summary

New Hampshire operates one of the most restrictive medical cannabis programs in the United States, serving approximately 8,500 registered patients through a tightly controlled network of four licensed Alternative Treatment Centers (ATCs). Established in 2013 under RSA 126-X, the program permits cannabis access for 23 qualifying conditions but maintains strict limitations on cultivation methods, product forms, and patient possession limits. In August 2026, the New Hampshire legislature overrode a gubernatorial veto to authorize greenhouse cultivation at licensed facilities, marking the first significant expansion of production capacity since program inception. The state remains one of 12 jurisdictions without adult-use legalization, creating unique market dynamics where medical operators face no recreational competition but operate under stringent regulatory oversight from the Department of Health and Human Services. With neighboring Maine, Massachusetts, and Vermont all operating adult-use markets, New Hampshire's medical-only framework faces mounting pressure for reform while generating approximately $45 million in annual sales across its four dispensaries.

Why This Matters

New Hampshire's medical cannabis program directly impacts 8,500 registered patients who depend on legal access to therapeutic cannabis, while the state's regulatory decisions influence a $45 million annual market and set precedent for medical-only programs nationwide. The program serves patients with debilitating conditions including cancer, multiple sclerosis, Crohn's disease, and post-traumatic stress disorder. For these individuals, the Alternative Treatment Center network represents the sole legal source of cannabis medicine in a state bordered by adult-use markets. The August 2026 veto override on greenhouse cultivation carries immediate implications for production capacity, product pricing, and supply chain resilience. From an industry perspective, New Hampshire's four licensed ATCs—Prime Alternative Treatment Centers, Sanctuary Medicinals, Temescal Wellness, and Granite State Dispensary—operate in a protected oligopoly. The state has issued no new licenses since 2016, creating barriers to entry that shelter existing operators while limiting patient choice. These facilities collectively employ approximately 320 workers and generate state tax revenue through the 5 percent sales tax applied to medical cannabis purchases. The greenhouse cultivation authorization represents the first major production expansion in 13 years, potentially increasing yields by 40-60 percent compared to indoor-only operations. Industry analysts project this could reduce wholesale costs by $200-$400 per pound, translating to 10-15 percent retail price decreases for patients who currently pay among the highest per-gram prices in New England. The program also serves as a case study in medical-only sustainability. As surrounding states transitioned to adult-use frameworks, New Hampshire maintained its medical-exclusive model, creating a natural experiment in program design. Policymakers in states considering medical-only approaches closely monitor New Hampshire's patient enrollment trends, product availability, and market stability.

Background and History

New Hampshire's path to medical cannabis legalization spanned more than a decade of legislative attempts, culminating in the 2013 passage of HB 573, which Governor Maggie Hassan signed into law on July 23, 2013.

Early Legislative Efforts (2009-2012)

The New Hampshire House of Representatives first passed medical cannabis legislation in 2009, only to see the bill fail in the Senate. Representative Evalyn Merrick introduced HB 648 that year, which would have established a patient registry and allowed home cultivation. The measure passed the House 214-125 but died in the Senate Health and Human Services Committee by a 3-2 vote. In 2010, the House again approved medical cannabis legislation through HB 1653, sponsored by Representative Cindy Rosenwald. This version eliminated home cultivation and proposed a state-run dispensary system. The bill passed the House 215-139 but faced opposition from Governor John Lynch, who indicated he would veto any medical cannabis measure. The Senate did not advance the legislation. The 2011-2012 legislative session saw renewed momentum. HB 442, introduced by Representative Rosenwald, passed the House 222-131 in March 2012. The bill proposed allowing four nonprofit Alternative Treatment Centers to cultivate and dispense cannabis to registered patients with qualifying conditions. The Senate passed an amended version 13-11 in May 2012, but Governor Lynch vetoed the measure on June 29, 2012, citing concerns about federal enforcement and inadequate regulatory safeguards.

Successful Passage (2013)

The 2013 legislative session brought a shift in political dynamics. Governor Maggie Hassan, who took office in January 2013, signaled openness to a tightly regulated medical cannabis program. Representative Rosenwald introduced HB 573, incorporating stricter controls than previous versions: no home cultivation, limited qualifying conditions, mandatory physician certification, and enhanced security requirements for cultivation facilities. The House passed HB 573 on March 20, 2013, by a vote of 222-110. The Senate approved the measure 18-6 on May 22, 2013. Governor Hassan signed the bill into law on July 23, 2013, making New Hampshire the 19th state to legalize medical cannabis. The law, codified as RSA 126-X, took effect immediately but required extensive rulemaking before patient access could begin.

Implementation Phase (2013-2016)

The Department of Health and Human Services spent 18 months developing administrative rules under He-P 805. The agency published proposed rules in January 2014, held public hearings through spring 2014, and finalized regulations in November 2014. These rules established application procedures for Alternative Treatment Center licenses, patient registration protocols, and operational requirements including seed-to-sale tracking. In July 2015, DHHS announced it would accept applications for four ATC licenses—one for each of the state's four designated regions (North Country, Central, Seacoast, and Southern). The application window ran from July 13 to August 14, 2015. The department received 19 applications and conducted extensive reviews including background checks, financial audits, and site inspections. DHHS awarded the four licenses on November 4, 2015: Prime Alternative Treatment Centers (North Country region), Sanctuary Medicinals (Central region), Temescal Wellness (Seacoast region), and Granite State Dispensary (Southern region). Each licensee received authorization to operate one cultivation facility and up to two dispensary locations within their designated region.

First Patient Sales (2016)

Prime Alternative Treatment Centers in Merrimack became the first facility to open, beginning patient sales on March 18, 2016—nearly three years after the law's passage. Sanctuary Medicinals in Plymouth opened in June 2016, followed by Temescal Wellness in Dover in August 2016. Granite State Dispensary in Salem completed the initial rollout in October 2016. The program launched with seven qualifying conditions: cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, muscular dystrophy, and Crohn's disease. Patients could possess up to two ounces of usable cannabis and were prohibited from cultivating their own medicine. Registered caregivers could assist up to five patients.

Program Expansions (2017-2023)

The legislature expanded qualifying conditions multiple times. In 2017, HB 197 added chronic pain, PTSD, and multiple sclerosis to the list. In 2019, SB 236 added Alzheimer's disease, autism, and Ehlers-Danlos syndrome. By 2023, the program recognized 23 qualifying conditions, including epilepsy, Parkinson's disease, and ulcerative colitis. In 2018, HB 1622 authorized ATCs to open second dispensary locations within their regions, increasing total dispensary count from four to eight. The law also permitted ATCs to manufacture cannabis-infused products including tinctures, topicals, and edibles, though smoking flower remained prohibited until 2020. HB 1648, passed in 2020, legalized smokable cannabis flower for medical patients, removing the previous restriction to non-combustible forms. This change aligned New Hampshire with the majority of medical cannabis states and addressed patient demand for whole-flower products. In 2022, the legislature passed SB 366, which increased patient possession limits from two ounces to three ounces and extended physician certifications from one year to two years for stable patients. The law also reduced the physician certification fee from $50 to $0, eliminating a financial barrier to program enrollment.

Greenhouse Cultivation Debate (2024-2026)

Prior to 2026, New Hampshire regulations required all cannabis cultivation to occur in fully enclosed indoor facilities with artificial lighting. This restriction, codified in He-P 805.10, aimed to prevent diversion and maintain security but significantly increased production costs. Indoor cultivation requires substantial electricity for lighting, climate control, and dehumidification, with energy costs representing 30-40 percent of total production expenses. In January 2024, Senator Shannon Chandley introduced SB 420, which would authorize ATCs to use greenhouse structures with supplemental lighting for cannabis cultivation. Proponents argued that greenhouse methods could reduce energy consumption by 50-70 percent while maintaining security through locked structures and surveillance systems. The New Hampshire Medical Cannabis Industry Association testified that greenhouse cultivation could increase yields by 40-60 percent per square foot compared to indoor methods. The Senate passed SB 420 on March 14, 2024, by a vote of 14-10. The House approved the measure 201-168 on May 9, 2024. However, Governor Chris Sununu vetoed the bill on June 15, 2024, stating that greenhouse structures posed "unacceptable security risks" and could facilitate diversion to neighboring states with adult-use markets. The legislature attempted to override the veto in the 2024 session but fell short of the required two-thirds majority in the House, with the override vote failing 232-152 (16 votes short of the 248 needed). Senator Chandley reintroduced the legislation as SB 315 in the 2025 session. This version included enhanced security provisions: reinforced greenhouse walls rated to withstand forced entry, mandatory motion sensors on all access points, and real-time video monitoring with 90-day retention. The Senate passed SB 315 on February 20, 2025, by a vote of 15-9. The House approved the amended version 215-160 on April 18, 2025. Governor Sununu again vetoed the measure on May 30, 2025, reiterating security concerns and arguing that the state should prioritize adult-use legalization over medical program expansion. The legislature adjourned before attempting an override. In the 2026 session, the legislature revived SB 315 and successfully overrode Governor Sununu's veto on August 20, 2026, with the House voting 251-124 and the Senate voting 17-7, both exceeding the two-thirds threshold. The override marked the first successful veto override on cannabis legislation in New Hampshire history and the first major cultivation reform since program inception.

Key Players

New Hampshire Department of Health and Human Services

The DHHS Division of Public Health Services administers the Therapeutic Cannabis Program under RSA 126-X, maintaining the patient registry, licensing Alternative Treatment Centers, and enforcing compliance with state regulations. The division employs six full-time staff dedicated to program oversight, including two compliance inspectors who conduct quarterly inspections of all ATC facilities. Director Patricia Tilley, who has led the division since 2019, oversees policy implementation and reports directly to DHHS Commissioner Lori Weaver. The department maintains the confidential patient registry, which as of July 2026 included 8,547 active registrations. DHHS issues registry identification cards valid for one year (or two years for stable patients under SB 366) and processes approximately 650 new patient applications monthly. The agency collects a $50 annual patient registration fee, generating approximately $425,000 in annual revenue that funds program administration.

Alternative Treatment Centers

Prime Alternative Treatment Centers, headquartered in Merrimack, operates two dispensaries serving the North Country and Central regions. The company cultivates approximately 2,500 plants across 15,000 square feet of indoor canopy space and employs 87 workers. Prime ATC reported $11.2 million in sales for fiscal year 2025. Sanctuary Medicinals, a subsidiary of Green Thumb Industries, operates dispensaries in Plymouth and Lebanon. The facility maintains 12,000 square feet of cultivation space and employs 76 workers. Sanctuary reported $10.8 million in sales for fiscal year 2025 and offers 45 distinct product SKUs including flower, tinctures, and topicals. Temescal Wellness, owned by Acreage Holdings, operates locations in Dover and Hudson. The company cultivates in 14,000 square feet of indoor space and employs 82 workers. Temescal reported $12.1 million in sales for fiscal year 2025 and has invested $1.8 million in facility upgrades since 2020. Granite State Dispensary, an independent operator, serves the Southern region from its Salem location. The facility maintains 10,000 square feet of cultivation space and employs 75 workers. Granite State reported $10.9 million in sales for fiscal year 2025.

Legislative Champions

Senator Shannon Chandley, a Democrat representing District 11 (Amherst, Merrimack, and Milford), has sponsored medical cannabis expansion legislation since 2020. Chandley, a former registered nurse, has focused on patient access issues including possession limits, qualifying conditions, and cultivation efficiency. She led the successful veto override effort in August 2026. Representative Erica Layon, a Republican representing Derry, has championed medical cannabis reform from a conservative perspective, emphasizing states' rights and reducing regulatory burdens on licensed businesses. Layon co-sponsored the greenhouse cultivation bill and delivered floor speeches highlighting energy cost savings and environmental benefits.

Advocacy Organizations

The Marijuana Policy Project maintains a New Hampshire chapter that has lobbied for medical cannabis expansion and adult-use legalization since 2009. MPP-NH provided testimony supporting greenhouse cultivation and organized grassroots campaigns that generated over 3,000 constituent contacts to legislators during the 2026 session. The New Hampshire Medical Cannabis Industry Association, formed in 2017, represents the four licensed ATCs and advocates for regulatory reforms that improve operational efficiency while maintaining compliance standards. The association commissioned an economic analysis demonstrating that greenhouse cultivation could reduce patient costs by 10-15 percent.

Opposition

Governor Chris Sununu, a Republican serving since 2017, has vetoed multiple medical cannabis expansion bills while expressing support for adult-use legalization. Sununu argues that New Hampshire should "leapfrog" medical expansion and move directly to a regulated adult-use market that generates broader tax revenue. His vetoes of greenhouse cultivation legislation cited security concerns and the need for comprehensive cannabis reform rather than incremental medical program changes. Smart Approaches to Marijuana, a national organization opposing cannabis legalization, maintains a New Hampshire presence and testified against greenhouse cultivation, arguing that outdoor or semi-outdoor growing increases diversion risk and undermines the medical nature of the program.

Legal and Regulatory Framework

New Hampshire's medical cannabis program operates under RSA 126-X, the Therapeutic Use of Cannabis statute, which establishes a closed-loop system where licensed Alternative Treatment Centers control all cultivation, processing, and dispensing.

Statutory Foundation

RSA 126-X, enacted in 2013 and amended multiple times, defines "therapeutic cannabis" as cannabis cultivated, processed, and dispensed for medical use by registered qualifying patients. The statute prohibits home cultivation, establishing ATCs as the exclusive legal source. Patients must obtain written certification from a licensed physician or APRN attesting that they suffer from a qualifying medical condition and that the potential benefits of cannabis outweigh the risks. The law establishes 23 qualifying conditions: cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pain, PTSD, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, autism, Ehlers-Danlos syndrome, opioid use disorder, agitation of Alzheimer's disease, moderate to severe insomnia, and elevated intraocular pressure. Physicians may also certify patients for other conditions if they determine cannabis is medically necessary. RSA 126-X:2 limits patient possession to three ounces of usable cannabis during any 10-day period. Patients may designate up to two caregivers, who may possess cannabis on behalf of up to five patients. The statute prohibits consumption in public places, on school grounds, or in motor vehicles.

Administrative Regulations

The Department of Health and Human Services promulgated comprehensive regulations under He-P 805, covering patient registration, physician certification, ATC licensing, cultivation standards, product testing, and security requirements. He-P 805.05 establishes patient registration procedures. Applicants must submit a physician certification form, proof of New Hampshire residency, and a $50 annual fee (waived for Medicaid recipients). DHHS issues registry identification cards within 15 business days of receiving complete applications. Cards include the patient's photograph, registry number, and expiration date but do not disclose the qualifying condition. He-P 805.10, as amended following the August 2026 veto override, now permits greenhouse cultivation structures meeting specific security standards. Greenhouses must have walls constructed of polycarbonate or glass rated to withstand 150 pounds per square foot of force, lockable entry points with electronic access logs, motion-activated lighting, and video surveillance covering all interior and exterior areas with 90-day retention. The amended rule requires ATCs to submit greenhouse construction plans to DHHS for approval 90 days before commencing construction. He-P 805.12 mandates testing of all cannabis products for potency, pesticides, heavy metals, microbial contaminants, and residual solvents. ATCs must use ISO-17025 accredited laboratories and may not sell products that exceed action levels for contaminants. Testing results must be available to patients via QR codes on product packaging.

Federal Law Conflicts

Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, 21 U.S.C. § 812. This creates ongoing legal tension between state-licensed medical cannabis operations and federal prohibition. However, the Rohrabacher-Farr Amendment (now Rohrabacher-Blumenauer), renewed annually in federal appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical cannabis programs operating in compliance with state law. New Hampshire ATCs cannot access traditional banking services due to federal prohibition, forcing many to operate on a cash basis or use limited banking relationships with state-chartered credit unions. The industry has advocated for passage of the SAFE Banking Act, which would provide safe harbor for financial institutions serving state-licensed cannabis businesses, but the measure has not become law as of August 2026.

Taxation

New Hampshire applies its 5 percent sales tax to medical cannabis purchases, generating approximately $2.25 million in annual tax revenue. Unlike adult-use states, New Hampshire does not impose excise taxes on medical cannabis cultivation or sales. ATCs face significant federal tax burdens under Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This results in effective federal tax rates of 60-75 percent of gross income for cannabis operators, substantially higher than other industries. ATCs can deduct only cost of goods sold, including direct cultivation expenses, but cannot deduct rent, salaries for non-cultivation staff, marketing, or other operating expenses.

State-by-State Context

New Hampshire's medical-only framework exists in stark contrast to its neighbors, all of which have legalized adult-use cannabis, creating unique cross-border dynamics and competitive pressures.

Maine

Maine legalized adult-use cannabis in 2016 through ballot initiative and launched retail sales in October 2020. The state operates a dual-track system with separate medical and adult-use programs. Maine's medical program, established in 1999, allows home cultivation of up to six mature plants and permits caregivers to serve unlimited patients. As of July 2026, Maine had licensed 387 adult-use retailers and 2,100 medical caregivers, creating a highly competitive market with wholesale prices averaging $1,200-$1,500 per pound—substantially lower than New Hampshire's $2,800-$3,200 per pound wholesale prices.

Massachusetts

Massachusetts voters approved adult-use legalization in 2016, with retail sales beginning in November 2018. The state operates separate medical and adult-use licensing systems under the Cannabis Control Commission. Massachusetts charges a 10.75 percent excise tax on adult-use sales plus local option taxes up to 3 percent, while medical sales are exempt from sales tax. As of July 2026, Massachusetts had licensed 298 adult-use retailers and 78 medical dispensaries. The proximity of Massachusetts dispensaries to the New Hampshire border—including locations in Amesbury, Salisbury, and Salem, Massachusetts—creates convenient access for New Hampshire residents willing to violate state law by purchasing out-of-state.

Vermont

Vermont legalized adult-use possession and home cultivation in 2018 through legislation, becoming the first state to legalize via legislature rather than ballot initiative. The state authorized commercial adult-use sales in 2020, with the first retailers opening in October 2022. Vermont's medical program, established in 2004, allows registered patients to cultivate up to nine plants or purchase from licensed dispensaries. As of July 2026, Vermont had licensed 47 adult-use retailers. Vermont does not share a direct border with New Hampshire's population centers, limiting cross-border shopping compared to Maine and Massachusetts.

Regional Comparison

State	Medical Program	Adult-Use Status	Home Cultivation	Dispensary Count	Average Retail Price (1/8 oz)
New Hampshire	Yes (2013)	No	Prohibited	8	$55-$65
Maine	Yes (1999)	Yes (2020)	6 plants	387 adult-use, 2,100 caregivers	$35-$45
Massachusetts	Yes (2012)	Yes (2018)	Medical only, 6 plants	298 adult-use, 78 medical	$45-$55
Vermont	Yes (2004)	Yes (2022)	6 plants	47 adult-use, 5 medical	$40-$50

The price differential between New Hampshire and neighboring states reflects both the limited competition within New Hampshire's four-ATC system and the higher production costs associated with indoor-only cultivation. Industry analysts estimate that 15-20 percent of New Hampshire's registered medical patients make cross-border purchases in Massachusetts or Maine, despite the legal risks, to access lower prices and broader product selection.

Market and Business Implications

The greenhouse cultivation authorization carries profound implications for New Hampshire's $45 million medical cannabis market, potentially reshaping production economics, wholesale pricing, and competitive dynamics among the four licensed ATCs.

Production Economics

Indoor cannabis cultivation in New Hampshire currently costs ATCs approximately $800-$1,200 per pound in direct production expenses, including electricity, climate control, nutrients, labor, and facility overhead. Energy costs alone represent 30-40 percent of this total, with high-intensity discharge or LED lighting consuming 30-50 watts per square foot of canopy for 12-18 hours daily. Greenhouse cultivation reduces energy consumption by 50-70 percent by leveraging natural sunlight for photosynthesis while maintaining climate control for temperature and humidity. Industry studies from Colorado and California demonstrate that greenhouse operations achieve production costs of $400-$700 per pound—a reduction of $300-$500 per pound compared to indoor methods. With New Hampshire ATCs collectively producing approximately 8,000-10,000 pounds annually, a transition to greenhouse methods could generate $2.4-$5 million in annual cost savings across the industry. These savings could flow to patients through lower retail prices, to operators through improved margins, or to reinvestment in facility expansion and product development. Greenhouse cultivation also increases yield per square foot. Indoor operations in New Hampshire average 1.2-1.5 pounds per 4x4 foot canopy area per harvest cycle (approximately 90-120 days). Greenhouse operations in other states achieve 1.8-2.4 pounds per equivalent area by extending vegetative growth periods and optimizing light exposure. This 40-60 percent yield increase could expand New Hampshire's total production capacity from 10,000 pounds to 14,000-16,000 pounds annually without requiring additional licensed facilities.

Wholesale and Retail Pricing

New Hampshire's wholesale cannabis prices currently range from $2,800-$3,200 per pound for premium flower, substantially higher than the $1,200-$1,800 range in mature adult-use markets like Colorado and Oregon. This premium reflects the limited competition among four ATCs and the high production costs of indoor cultivation. If greenhouse cultivation reduces production costs by $300-$500 per pound and increases yields by 40-60 percent, basic economic theory suggests wholesale prices should decline by 10-20 percent to $2,240-$2,880 per pound. This assumes ATCs pass some cost savings to patients while retaining improved margins. Retail prices for patients currently average $55-$65 per eighth-ounce ($440-$520 per ounce) for premium flower. A 10-15 percent retail price reduction would bring prices to $47-$59 per eighth-ounce, improving affordability for the 8,500 registered patients. For a patient consuming one ounce monthly, this represents annual savings of $480-$960.

Competitive Dynamics

The four ATCs vary in their capacity to implement greenhouse cultivation. Temescal Wellness and Prime ATC own larger land parcels that can accommodate 10,000-15,000 square foot greenhouse structures. Sanctuary Medicinals operates in a more constrained urban location but has indicated plans to lease additional land for greenhouse development. Granite State Dispensary faces the most significant real estate constraints in the densely developed Salem area. ATCs that move quickly to implement greenhouse cultivation could gain 12-18 month competitive advantages through lower production costs and increased inventory, potentially capturing market share from slower-moving competitors. This dynamic may accelerate consolidation pressures, with larger multi-state operators like Green Thumb Industries (owner of Sanctuary) and Acreage Holdings (owner of Temescal) leveraging capital access to build greenhouse infrastructure faster than independent operators. The greenhouse authorization may also influence New Hampshire's broader cannabis policy trajectory. If greenhouse cultivation successfully reduces prices and increases supply without security incidents, it may strengthen the case for maintaining the medical-only framework rather than transitioning to adult-use. Conversely, if greenhouse implementation proves slow or fails to materialize significant patient benefits, it may fuel arguments that comprehensive adult-use legalization is necessary to achieve competitive pricing and product diversity.

Capital Investment

Constructing a compliant greenhouse facility requires substantial capital investment. Industry estimates suggest that a 10,000 square foot greenhouse meeting New Hampshire's security standards costs $1.5-$2.5 million, including site preparation, structural construction, climate control systems, security infrastructure, and cultivation equipment. The four ATCs collectively may invest $6-$10 million in greenhouse development over the next 24-36 months. This capital deployment will likely come from a mix of retained earnings, operator equity contributions, and private debt financing (as federal prohibition prevents access to traditional bank loans). Multi-state operators like Green Thumb Industries and Acreage Holdings may fund their New Hampshire subsidiaries through internal capital allocation, while independent operators like Granite State Dispensary may seek private equity partnerships or revenue-based financing. The return on investment timeline for greenhouse construction depends on production cost savings and yield increases. If an ATC invests $2 million in a greenhouse that reduces production costs by $400 per pound and increases annual production by 2,000 pounds, the facility generates $800,000 in annual cost savings, yielding a 2.5-year payback period before considering increased revenue from higher production volumes.

What Experts Say

Industry analysts, patient advocates, and policy experts have offered varied perspectives on the greenhouse cultivation authorization and its implications for New Hampshire's medical cannabis program. Andrew Freedman, a cannabis policy consultant who served as Colorado's first director of marijuana coordination, said the New Hampshire veto override represents a pragmatic step toward sustainable medical cannabis production. According to Freedman, greenhouse cultivation has proven successful in Colorado and California by reducing energy consumption while maintaining product quality and security. He noted that New Hampshire's enhanced security requirements for greenhouse structures address legitimate diversion concerns while allowing operators to achieve production efficiencies. Karen O'Keefe, director of state policies at the Marijuana Policy Project, said the veto override demonstrates growing legislative consensus that medical cannabis programs must evolve to serve patients effectively. O'Keefe noted that New Hampshire's medical program has operated for a decade without significant diversion or public safety incidents, establishing a track record that supports expanded cultivation methods. She emphasized that greenhouse authorization should be followed by additional reforms including increased ATC licenses and home cultivation rights for patients in rural areas far from dispensaries. Matt Karnes, founder of GreenWave Advisors, said the greenhouse authorization will likely improve margins for New Hampshire ATCs but may not translate to significant retail price reductions in the near term. According to Karnes, the four-ATC oligopoly structure limits competitive pressure to pass cost savings to patients. He projected that ATCs will retain 60-70 percent of production cost savings as improved EBITDA margins while reducing retail prices by 5-10 percent to maintain patient loyalty and preempt calls for additional licenses. Dustin McDonald, executive director of the New Hampshire Medical Cannabis Industry Association, said the veto override validates the industry's multi-year effort to demonstrate that greenhouse cultivation can meet security standards while improving sustainability. McDonald noted that New Hampshire ATCs collectively consume approximately 4.2 million kilowatt-hours of electricity annually for indoor cultivation, generating a carbon footprint equivalent to 600 homes. He projected that greenhouse cultivation could reduce energy consumption by 2.5-3 million kilowatt-hours annually, aligning with New Hampshire's climate goals. Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and medical cannabis researcher, said the greenhouse authorization addresses a significant barrier to patient access—high costs driven by inefficient production methods. According to Grinspoon, many patients with chronic pain, PTSD, and other qualifying conditions live on fixed incomes and struggle to afford $400-$500 per ounce cannabis prices. He noted that cost barriers drive some patients to unregulated markets or to forgo cannabis treatment entirely, undermining the medical program's therapeutic goals. Kevin Sabet, president of Smart Approaches to Marijuana, said the greenhouse authorization increases diversion risk and undermines the medical nature of New Hampshire's program. Sabet argued that outdoor or semi-outdoor cultivation is appropriate for agricultural commodities but not for controlled medical substances. He contended that New Hampshire should focus on pharmaceutical-grade cannabis products rather than expanding cultivation capacity for smokable flower.

What's Next

The greenhouse cultivation authorization takes effect immediately following the August 20, 2026 veto override, but practical implementation will unfold over 18-24 months as ATCs design facilities, obtain DHHS approvals, and commence construction.

Regulatory Implementation Timeline

The Department of Health and Human Services must finalize amendments to He-P 805.10 by October 1, 2026, establishing detailed technical specifications for greenhouse structures, security systems, and environmental controls. DHHS has indicated it will convene a technical working group including ATC operators, security consultants, and horticultural engineers to develop standards that balance security, sustainability, and operational feasibility. ATCs may submit greenhouse construction plans to DHHS beginning November 1, 2026. The department has committed to reviewing plans within 60 days and providing written approval or requests for modifications. Industry sources indicate that at least three of the four ATCs plan to submit initial plans by December 2026, targeting construction commencement in spring 2027.

Construction and Operational Timeline

Greenhouse construction typically requires 6-9 months from groundbreaking to operational readiness, depending on structure size and site conditions. ATCs beginning construction in April-May 2027 could achieve operational status by November 2027-February 2028. The first greenhouse-cultivated cannabis would reach patients approximately 120 days after planting, placing initial sales in March-June 2028. Industry analysts project that 40-50 percent of New Hampshire's medical cannabis production will shift to greenhouse methods by the end of 2028, with full transition potentially occurring by 2030. The pace of transition depends on capital availability, real estate constraints, and market demand dynamics.

Legislative Outlook

The successful veto override may embolden medical cannabis expansion advocates to pursue additional reforms in the 2